Its not a big deal, says Dr
Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
Inspired by Nature, Engineered for Longevity: The Birth of GLP-1 Agonists The discovery of exendin-4 paved the way for the development of the first GLP-1 receptor agonist, exenatide (Byetta), which was directly derived from the Gila monster's venom
Studies in mice showed that pharmacological blockade or genetic knockout of GLP1Rs in the central nervous system (CNS) could block or significantly attenuate GLP1RA weight loss and food intake suppression, highlighting the necessity of central GLP1Rs 69
GLP-1 and GIP receptors are present in areas of the body where estrogen also acts
Most patients will notice some body weight loss in the first month, the real game changing benefits are usually fully noticed starting after three months of treatment
